Auria Biopankki

What Auria Biopankki does

Auria Biopankki is a Finnish hospital biobank, founded in 2012 and licensed in 2014, operating as a regional service area within Tyks Laboratoriot under the Varsinais-Suomen hyvinvointialue (Varha) public welfare authority. It collects, stores, and distributes human biological samples — including blood, tissue, and derived products such as the OvaCure ovarian cancer organoid collection — and links them to associated clinical data across three Finnish hospital districts (Varsinais-Suomi, Satakunta, and Vaasa). Following the 2024 merger with Terveystalo's biobank operations, it holds over one million samples, making it Finland's largest biobank and the first in Finland and the Nordics to achieve FINAS accreditation (B001) under SFS-EN ISO 20387:2020.

The company serves three customer segments: academic and clinical researchers (primarily via the University of Turku), pharmaceutical and diagnostic companies, and citizens/patients who consent to sample storage during routine clinical procedures. Researchers access samples through the Fingenious® digital platform and a scientific steering group approval process, while citizens provide consent through digital channels (the Varha and Sata mobile applications) or paper forms during healthcare visits. The technology stack centres on biobank infrastructure operating under the strictest international biobanking standard, with no disclosed AI/ML capabilities.

Auria Biopankki's business model combines public funding through the Finnish regional welfare authority with commercial revenue from professional services — specifically sample and data provision fees, and collaborative research partnerships such as the Aqsens Health bladder-cancer biosensor project. Pricing is not publicly disclosed and access is gated by application, suggesting negotiated, project-based contracts with academic and industry clients rather than high-volume transactional sales. The entity is government-owned, not venture-backed, and is governed as public healthcare infrastructure.

Name

Auria Biopankki

Legal name

Auria Biopankki

Website

https://auriabiopankki.fi

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Auria Biopankki is a Finnish hospital biobank under Varha that collects, stores, and distributes over one million human biological samples and clinical data to academic researchers and pharmaceutical and diagnostic companies across three regional health districts.

Ownership category

akta.pro rank

Product category

Biobanking Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biobank & Biospecimen Management LIMS (HLACAMAG)

akta.pro secondary industries

Sample / Biorepository & Biobank Informatics (Chain-of-Custody) (HLAGAJAH), Specimen Referral, Transport & Chain-of-Custody Coordination Networks (HLAJAIAO), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)

Keywords

• Human biobank services
• Biomedical sample storage
• Clinical research samples
• Biobank data access
• Organoid culture collections

Headquarters

HQ city

Turku

HQ country

Finland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Sample and data provision services: Auria Biopankki provides high-quality human-derived samples and associated clinical data to biomedical researchers, including academic institutions, pharmaceutical companies, and diagnostic companies. Revenue is generated through service fees for sample processing, preparation, and delivery under approved research protocols.
2. Research collaboration services: The biobank engages in collaborative research partnerships with healthcare providers and technology companies, such as the joint bladder cancer detection research with Aqsens Health Oy.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Auria Biopankki collects, stores, and distributes human biological samples (blood, tissue, and other specimens) along with associated clinical data to academic researchers and pharmaceutical/diagnostic companies. Following its 2024 merger with Terveystalo's biobank operations, it holds over one million samples across three Finnish hospital districts. Access is governed by scientific steering group approval through the Fingenious® platform and operates under FINAS accreditation (SFS-EN ISO 20387:2020).

Product overview

Auria Biopankki is Finland's oldest hospital biobank, operating as part of Tyks Laboratory Services in connection with the University of Turku. The core offering is a biobank containing over one million human samples used for biomedical research. The product portfolio includes the main Auria Biopankki service for storing and distributing samples to researchers, the OvaCure Collection for ovarian cancer organoid cultures, the Fingenious® platform for researchers to request samples, mobile applications (Varha-sovellus and Sata-sovellus) for citizens to provide digital consent, an interactive consent map (Suostumuskartta), and sample collection services at TUAS Lab.

Differentiator

Problem solved

Functional benefit

Products and services

• Auria Biopankki Biobanking Service Core biobanking service that collects, stores, and distributes human biological samples (blood, tissue, and other specimens) and associated clinical data for biomedical research. Serving academic researchers at universities and university hospitals, plus pharmaceutical and diagnostic companies, with sample access governed by scientific steering group approval.
• OvaCure Collection A specialized collection of stable and well-characterised organoid cultures derived from patient-derived high-grade serous ovarian tumour samples, made available to researchers studying ovarian cancer.
• Fingenious® Platform Digital platform used by researchers to discover available sample collections and submit sample requests to Auria Biopankki for scientific research purposes.

Quantifiable outcome

• Over 1 million samples available for research following the merger with Terveystalo biobank

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature2 records

Partnerships

Eleven partnerships are on record, tiered flagship, core and minor.

• Terveystalo Biopankki (merged into Auria)flagshipStrategic or Co-development Partner · 1 January 2024Terveystalo's biobank operations transferred to Varsinais-Suomen hyvinvointialue (Varha) and merged into Auria Biopankki. This merger created Finland's largest biobank with over one million samples. Terveystalo's biobank samples and donor registry were incorporated into Auria's operations.
• Turku University (Turun yliopisto)coreStrategic or Co-development PartnerOne of the founding organisations of Auria Biopankki. Provides research expertise, academic infrastructure, and researchers who access biobank samples. The biobank is located in the University of Turku's hospital complex.
• Tyks Laboratoriot (Tyks Laboratory)coreStrategic or Co-development PartnerAuria Biopankki is one of five service areas within the Tyks Laboratory results group. The biobank operates within the Tyks hospital ecosystem, integrating sample collection with clinical care.
• Varsinais-Suomen hyvinvointialue (Varha)coreStrategic or Co-development PartnerThe wellbeing services county that owns Auria Biopankki following the 2024 administrative restructuring. Varha provides the administrative and healthcare infrastructure within which the biobank operates. Citizens can give biobank consent via the Varha app.
• Aqsens Health OycoreStrategic or Co-development PartnerAqsens Health Oy, Tyks, and Auria Biopankki are collaborating on a research project to validate the use of Aqsens-developed phage-biosensors for detecting and classifying bladder cancer from urine samples. The study focuses on monitoring bladder cancer progression and detecting disease recurrence non-invasively.
• Turku University of Applied Sciences (TUAS)minorStrategic or Co-development PartnerTUAS operates the TUAS Lab (Medisiina D, Turku) where citizens can give dedicated biobank blood samples by appointment. Bioanalyist students perform sample collection under supervision. The service is provided free of charge to sample donors.
• Fingenious®coreTechnology or IntegrationFingenious® is a digital platform used by researchers to discover and request access to biobank samples. It is referenced as the primary interface for researchers seeking sample access from Auria Biopankki.
• OvaCureminorStrategic or Co-development PartnerOvaCure is a collection of stable, well-characterised organoid cultures derived from patient-derived high-grade serous ovarian tumour samples held within Auria Biopankki. The collection was published in a scientific journal (ScienceDirect).
• iCan National Cancer ProgrammeminorStrategic or Co-development PartnerThe iCan national programme allocated 2.5 million euros in funding to regional cancer centres for biobank projects. Auria Biopankki is involved in this programme alongside other Finnish biobanks and cancer centres.
• Satakunnan hyvinvointialue (Satakunnan HVA)minorStrategic or Co-development PartnerOne of the original founding hospital districts. Citizens of Satakunnan can give biobank consent via the Sata app. Staff presence maintained in Pori.
• Vaasan keskussairaala (Vaasa Central Hospital)minorStrategic or Co-development PartnerOne of the original founding hospital districts. The biobank operates in association with Vaasan keskussairaala for sample collection in the Vaasa region.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• deCODE genetics (Amgen): Population-scale human genetics and biobanking company. Comparable in providing well-characterised human samples and health data to pharmaceutical and academic researchers, but operates commercially at a much larger scale with proprietary genomic profiling capabilities.
• BioIVT: Global supplier of human biological specimens and disease-state samples to pharma and diagnostic researchers. Comparable in offering high-quality human samples for drug development and diagnostic validation, but operates as a commercial sample vendor rather than a hospital biobank.
• Brooks Life Sciences / BioStorage Technologies: Specialist in sample management, biobanking services, and cold-chain logistics for life science research. Comparable in offering biorepository and chain-of-custody services, though focuses more on sample storage logistics than on hospital-based clinical collection.
• BBMRI-ERIC: European biobanking research infrastructure consortium that federates national biobanks, including Auria-adjacent Finnish nodes. Comparable in aggregating biobank samples for cross-border research, but operates as a federation rather than a sample provider directly.
• UK Biobank: Large-scale population biobank with deep clinical phenotyping and established pharma research partnerships. Comparable in offering human samples and health data for biomedical research, but operates at national-population scale and is globally recognised, whereas Auria is regional.

Direct peers

• Biobank Graz (Medical University of Graz): University-hospital biobank operating under ISO-accredited quality standards, providing human samples for biomedical research. Closely comparable in hospital-embedded operating model, ISO accreditation status, and academic-pharma customer mix.
• Helsinki Biobank (HUS): Finland's largest hospital biobank by catchment prior to Auria's Terveystalo merger, operating within Helsinki University Hospital (HUS). Closely comparable in Finnish regulatory framework, hospital integration, and competing for the same pharma and academic sample requests.
• Karolinska Institutet Biobank: Swedish hospital biobank supporting biomedical research with clinically annotated human samples. Directly comparable in hospital-anchored Nordic operating model, regulatory oversight, and customer base of academic and pharma researchers.

Emerging players

• Crown Bioscience (JSR Life Sciences): Translational research services company offering patient-derived organoid models, xenograft platforms, and biobank-derived samples for oncology research. Comparable via the OvaCure Collection's organoid angle, though operates as a global commercial CRO rather than a public hospital biobank.

Regional players

• Finnish Biobanks (FinnGen / BBMRI.fi network): National network of Finnish hospital biobanks, including Auria's peers such as Helsinki Biobank, THL Biobank, and Terveystalo's prior operations. Directly comparable in operating model (hospital-anchored, ISO-aligned, public-sector ownership) and in competing for the same Finnish patient populations and pharma research contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/auriabiopankki
• Facebookfacebook.com/biopankki
• LinkedInlinkedin.com/company/auria-biobank

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Auria Biopankki